| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Erik B Oleson, Lindsey R Hamilton, Devan M Gome. Cannabinoid Modulation of Dopamine Release During Motivation, Periodic Reinforcement, Exploratory Behavior, Habit Formation, and Attention. Frontiers in synaptic neuroscience. vol 13. 2021-06-29. PMID:34177546. |
exogenous cannabinoids, like the primary psychoactive component of cannabis, delta-9-tetrahydrocannabinol, produce their effects by acting at binding sites for naturally occurring endocannabinoids. |
2021-06-29 |
2023-08-13 |
Not clear |
| Esraa Aly, Willias Masoch. Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review. IBRO neuroscience reports. vol 10. 2021-06-29. PMID:34179865. |
cannabis, phytocannabinoids, and the endocannabinoids such n-arachidonoylethanolamine (anandamide; aea) and 2-arachidonoylglycerol (2-ag), produce some of their effects via cannabinoid receptors (cbrs). |
2021-06-29 |
2023-08-13 |
human |
| Esraa Aly, Willias Masoch. Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review. IBRO neuroscience reports. vol 10. 2021-06-29. PMID:34179865. |
we searched pubmed, google scholar, clinicaltrials.gov and clinicaltrialsregister.eu using various key words and their combinations for published papers that studied hiv-np and cannabis, cannabinoids, or endocannabinoids up to 27th december 2020. |
2021-06-29 |
2023-08-13 |
human |
| Esraa Aly, Willias Masoch. Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review. IBRO neuroscience reports. vol 10. 2021-06-29. PMID:34179865. |
two clinical trials demonstrated greater efficacy of smoked cannabis over placebo in alleviating hiv-np, whereas another clinical trial demonstrated that cannabidivarin, a cannabinoid that does not activate cbrs, did not reduce hiv-np. |
2021-06-29 |
2023-08-13 |
human |
| Joji Suzuki, Roger D Weis. Cannabinoids for the Treatment of Opioid Use Disorder: Where is the Evidence? Journal of addiction medicine. vol 15. issue 2. 2021-06-28. PMID:32909980. |
with the growing public interest in the potential therapeutic benefits of cannabis and cannabinoids in the treatment of opioid use disorder (oud), some states have now either added or proposed to add oud as an indication for their state's medical marijuana program. |
2021-06-28 |
2023-08-13 |
Not clear |
| Joji Suzuki, Roger D Weis. Cannabinoids for the Treatment of Opioid Use Disorder: Where is the Evidence? Journal of addiction medicine. vol 15. issue 2. 2021-06-28. PMID:32909980. |
however, these initiatives are based on weak evidence which at present do not support the listing of cannabis or cannabinoids as a treatment for oud. |
2021-06-28 |
2023-08-13 |
Not clear |
| Joji Suzuki, Roger D Weis. Cannabinoids for the Treatment of Opioid Use Disorder: Where is the Evidence? Journal of addiction medicine. vol 15. issue 2. 2021-06-28. PMID:32909980. |
nevertheless, studying the potential therapeutic applications of carefully chosen components of cannabis or cannabinoids to treat specific aspects of oud is not without scientific merit. |
2021-06-28 |
2023-08-13 |
Not clear |
| Joji Suzuki, Roger D Weis. Cannabinoids for the Treatment of Opioid Use Disorder: Where is the Evidence? Journal of addiction medicine. vol 15. issue 2. 2021-06-28. PMID:32909980. |
the potential therapeutic applications of cannabis and cannabinoids in the treatment of oud are worthy of further study, but it should be conducted with the same rigor that we expect of all pharmaceutical products. |
2021-06-28 |
2023-08-13 |
Not clear |
| Joji Suzuki, Roger D Weis. Cannabinoids for the Treatment of Opioid Use Disorder: Where is the Evidence? Journal of addiction medicine. vol 15. issue 2. 2021-06-28. PMID:32909980. |
until we have more research to show their efficacy, policy makers and clinicians should refrain from portraying cannabis and cannabinoids as evidence-based treatments for oud. |
2021-06-28 |
2023-08-13 |
Not clear |
| Jillian L Capodice, Steven A Kapla. The endocannabinoid system, cannabis, and cannabidiol: Implications in urology and men's health. Current urology. vol 15. issue 2. 2021-06-26. PMID:34168527. |
the endocannabinoid system, cannabis, and cannabidiol: implications in urology and men's health. |
2021-06-26 |
2023-08-13 |
human |
| Karma Rabgay, Neti Waranuch, Nathorn Chaiyakunapruk, Ratree Sawangjit, Kornkanok Ingkaninan, Piyameth Dilokthornsaku. The effects of cannabis, cannabinoids, and their administration routes on pain control efficacy and safety: A systematic review and network meta-analysis. Journal of the American Pharmacists Association : JAPhA. vol 60. issue 1. 2021-06-25. PMID:31495691. |
the effects of cannabis, cannabinoids, and their administration routes on pain control efficacy and safety: a systematic review and network meta-analysis. |
2021-06-25 |
2023-08-13 |
Not clear |
| Karma Rabgay, Neti Waranuch, Nathorn Chaiyakunapruk, Ratree Sawangjit, Kornkanok Ingkaninan, Piyameth Dilokthornsaku. The effects of cannabis, cannabinoids, and their administration routes on pain control efficacy and safety: A systematic review and network meta-analysis. Journal of the American Pharmacists Association : JAPhA. vol 60. issue 1. 2021-06-25. PMID:31495691. |
to determine the effects of cannabis, cannabinoids, and their administration routes on pain and adverse euphoria events. |
2021-06-25 |
2023-08-13 |
Not clear |
| Elizabeth M Mudge, Paula N Brow. Determination of Cannabinoids in Cannabis sativa Dried Flowers and Oils by LC-UV: Single-Laboratory Validation, First Action 2018.10. Journal of AOAC International. vol 103. issue 2. 2021-06-25. PMID:31561754. |
determination of cannabinoids in cannabis sativa dried flowers and oils by lc-uv: single-laboratory validation, first action 2018.10. |
2021-06-25 |
2023-08-13 |
Not clear |
| Elizabeth M Mudge, Paula N Brow. Determination of Cannabinoids in Cannabis sativa Dried Flowers and Oils by LC-UV: Single-Laboratory Validation, First Action 2018.10. Journal of AOAC International. vol 103. issue 2. 2021-06-25. PMID:31561754. |
legalization of cannabis across many u.s. states and in canada had led to an urgent need for validated analytical methods for the quantitation of cannabinoids in cannabis sativa l. flowers and finished products. |
2021-06-25 |
2023-08-13 |
Not clear |
| Jessica W Skelley, Crystal M Deas, Zachary Curren, Jonathan Enni. Use of cannabidiol in anxiety and anxiety-related disorders. Journal of the American Pharmacists Association : JAPhA. vol 60. issue 1. 2021-06-25. PMID:31866386. |
cannabidiol (cbd) has a proposed novel role in the management of anxiety owing to its actions on the endocannabinoid system. |
2021-06-25 |
2023-08-13 |
Not clear |
| Alyssa F DeLarge, Peter J Winsaue. Effects of ∆ Hormones and behavior. vol 127. 2021-06-25. PMID:33160960. |
effects of ∆ the effects of marijuana's major psychoactive cannabinoid, ∆ |
2021-06-25 |
2023-08-13 |
Not clear |
| Michael W DeGregorio, Susan A Audino, Edward Montoya, Aron Phong, Chiao-Jung Kao, Gregory T Wur. Development and Validation of a Liquid Chromatography High-Resolution Mass Spectrometry (LC-HRMS) Bioanalytical Method for Quantifying Cannabinoids in Whole Blood: Application for Determining Recent Cannabis Use. Journal of AOAC International. vol 103. issue 3. 2021-06-25. PMID:33241370. |
development and validation of a liquid chromatography high-resolution mass spectrometry (lc-hrms) bioanalytical method for quantifying cannabinoids in whole blood: application for determining recent cannabis use. |
2021-06-25 |
2023-08-13 |
Not clear |
| Mary-Ann Fitzcharles, Emmanouil Rampakakis, John Sampalis, Yoram Shir, Martin Cohen, Michael Starr, Winfried Häuse. Use of medical cannabis by patients with fibromyalgia in Canada after cannabis legalisation: a cross-sectional study. Clinical and experimental rheumatology. vol 39 Suppl 130. issue 3. 2021-06-25. PMID:33938797. |
cannabinoids, including medical cannabis (mc) may have potential to fill this gap. |
2021-06-25 |
2023-08-13 |
Not clear |
| Francisco Arias Horcajadas, José Ramón Dávila Píriz, Alba Parra González, Sergio Sánchez Romero, Eva Sánchez-Morla, Israel Ampuero Sánchez, José Antonio Ramos Atanc. Cannabinoid receptor type 2 gene is associated with comorbidity of schizophrenia and cannabis dependence and fatty acid amide hydrolase gene is associated with cannabis dependence in the Spanish population. Adicciones. vol 0. issue 0. 2021-06-25. PMID:34171108. |
we analysed different cannabinoid gene polimorphisms from non-substance using patients diagnosed with schizophrenia (n = 379), schizophrenic patients with cannabis use disorders (n = 124), cannabis users who did not have psychoses (n = 71), and 316 controls from various spanish hospitals and health centres. |
2021-06-25 |
2023-08-13 |
human |
| Cathrin Rohleder, Franziska Pahlisch, Rudolf Graf, Heike Endepols, F Markus Lewek. Different pharmaceutical preparations of Δ Addiction biology. vol 25. issue 3. 2021-06-24. PMID:30938471. |
different pharmaceutical preparations of Δ based on the contribution of the endocannabinoid system to the pathophysiology of schizophrenia, the primary pro-psychotic ingredient of cannabis sativa, Δ-9-tetrahydrocannabinol (Δ-9-thc), is used in preclinical as well as clinical research to mimic schizophrenia-like symptoms. |
2021-06-24 |
2023-08-13 |
human |